Streptococcus pneumoniae in the USA: In vitro susceptibility and pharmacodynamic analysis

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 5, 2000, Pages 623-631

  Mason Jr , Edward O ^a,b   Lamberth, Linda B ^a   Kershaw, Nerisa L ^a,b   Prosser, Barbara La T ^c   Zoe, Annette ^c   Ambrose, Paul G ^c  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CEFACLOR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; ERYTHROMYCIN; LORACARBEF; MACROLIDE; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG BLOOD LEVEL; EAR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; RESPIRATORY SYSTEM; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0342265156     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.5.623     Document Type: Article

References (30)

1. Butler, J. C., Hofmann, J., Cetron, M. S., Elliott, J. A., Facklam, R. R. & Breiman, R. F. (1996). The continued emergence of drug-resistant Streptococcuspneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. Journal of Infectious Diseases 174, 986-93.
2. Chesney, P. J. (1992). The escalating problem of antimicrobial resistance in Streptococcus pneumoniae. American Journal of Diseases of Children 146, 912-6.
3. Doern, G. V., Brueggemann, A., Holley, H. P., Jr & Rauch, A. M. (1996). Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy 40, 1208-13.
4. Mason, E. O., Jr & Kaplan, S. L. (1995). Penicillin-resistant pneumococci in the United States. Pediatric Infectious Disease Journal 14, 1017-8.
5. American Academy of Pediatrics Committee on Infectious Diseases. (1997). Therapy for children with invasive pneumococcal infections. Pediatrics 99, 289-99.
6. National Committee for Clinical Laboratory Standards. (1998). Performance Standards for Antimicrobial Susceptibility Testing -Eighth Informational Supplement: M100-S8. NCCLS, Wayne, PA.
7. Dagan, R., Abramson, O., Leibovitz, E., Lang, R., Goshen, S., Greenberg, D. et al. (1996). Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatric Infectious Disease Journal 15, 980-5.
8. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Fourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA.
9. Saez-Llorens, X., Shyu, W. C., Shelton, S., Kumiesz, H. & Nelson, J. (1990). Pharmacokinetics of cefprozil in infants and children. Antimicrobial Agents and Chemotherapy 34, 2152-5.
10. Kafetzis, D. A., Carabinos, C., Bairamis, T. & Apostolopoulos, N. (1993). Diffusion of four oral cephalosporins into the middle ear exudate (MEE) of children suffering from acute otitis media (AOM). In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1993. Abstract 941, p. 291. American Society for Microbiology, Washington, DC.
11. Foulds, G., Luke, D. R., Teng, R., Willavize, S. A., Friedman, H. & Curatolo, W. J. (1996). The absence of an effect of food on the bioavailabilty of azithromycin administered as tablets, sachet or suspension. Journal of Antimicrobial Chemotherapy 37, Suppl. C, 37-44.
12. Mason, E. O., Jr, Lamberth, L., Lichenstein, R. & Kaplan, S. L. (1995). Distribution of Streptococcus pneumoniae resistant to penicillin in the USA and in-vitro susceptibility to selected oral antibiotics. Journal of Antimicrobial Chemotherapy 36, 1043-8.
13. Doern, G. V. (1996). Antimicrobial resistance among lower respiratory tract isolates of Haemophilus influenzae: results of a 1992-93 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 59-69.
14. Kaplan, S. L., Mason, E. 0., Jr, Barson, W. J., Wald, E. R., Arditi, M., Tan, T. Q. et al. (1998). Three-year multicenter surveillance of systemic pneumococcal infections in children. Pediatrics 102, 538-45.
15. Kaplan, S. L. & Mason, E. O., Jr (1998). Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clinical Microbiology Reviews 11, 628-44.
16. Thornsberry, C., Brown, S. D., Yee, Y. C., Bouchillon, S. K., Marier, J. K. & Rich, T. (1993). Increasing penicillin resistance in Streptococcus pneumoniae in the U.S.: effect on susceptibility to oral cephalosporins. Infections in Medicine 10, Suppl. D, 15-24.
17. Doern, G. V., Pfaller, M. A., Kugler, K., Freeman, J. & Jones, R. N. (1998). Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clinical Infectious Diseases 27, 764-70.
18. Dagan, R., Abramson, O., Leibovitz, E., Greenberg, D., Lang, R., Goshen, S. et al. (1997). Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? Journal of Infectious Diseases 176, 1253-9.
19. Craig, W. A. (1995). Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagnostic Microbiology and Infectious Disease 22, 89-96.
20. Drusano, G. L. (1988). Role of pharmacokinetics in the outcome of infections. Antimicrobial Agents and Chemotherapy 32, 289-97.
21. Eagle, H., Fleischman, R. & Levy, M. (1953). 'Continuous' vs. 'Discontinuous' therapy with penicillin. The effect of the interval between injections on therapeutic efficacy. New England Journal of Medicine 248, 481-8.
22. Craig, W. (1993). Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens. European Journal of Clinical Microbiology and Infectious Diseases 12, Suppl. 1, S6-8.
23. Nicolau, D. P., Freeman, C. D., Belliveau, P. P., Nightingale, C. H., Ross, J. W. & Quintiliani, R. (1995). Experience with a once-daily aminoglycoside program administered to 2, 184 adult patients. Antimicrobial Agents and Chemotherapy 39, 650-5.
24. Preston, S. L., Drusano, G. L., Berman, A. L., Fowler, C. L., Chow, A. T., Dornseif, B. et al. (1998). Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Journal of the American Medical Association 279, 125-9.
25. Lacy, M. K., Owens, R. C., Xu, X., Nicolau, D. P., Quintiliani, R. & Nightingale, C. H. (1997). Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin and cefuroxime axetil against Streptococcus pneumoniae. International Journal of Antimicrobial Agents 10, 279-83.
26. Craig, W. A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing in mice and men. Clinical Infectious Diseases 26, 1-12.
27. Craig, W. A. & Andes, D. (1996). Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatric Infectious Disease Journal 15, 255-9.
28. Ambrose, P. G., Quintiliani, R., Nightingale, C. H. & Nicolau, D. P. (1998). Continuous vs. intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia. Infectious Diseases in Clinical Practice 7, 463-70.
29. Barry, A. L., Fuchs, P. C. & Brown, S. D. (1997). Macrolide resistance among Streptococcus pneumoniae and Streptococcus pyogenes isolates from out-patients in the USA. Journal of Antimicrobial Chemotherapy 40, 139-40.
30. Barry, A. L., Pfaller, M. A., Fuchs, P. C. & Packer, R. R. (1994). In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993. Antimicrobial Agents and Chemotherapy 38, 2419-25.